Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.8892.4802
Address
25-37 Chapman Street Building 10 Blackburn North, Victoria (VIC) 3131
Description
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.17
Trade Value (12mth)
AU$13,745.00
1 week
-1.27%
1 month
1.3%
YTD
1.3%
1 year
-1.27%
All time high
15.60
EPS 3 yr Growth
-19.80%
EBITDA Margin
-175.00%
Operating Cashflow
-$6m
Free Cash Flow Return
-34.10%
ROIC
-42.50%
Interest Coverage
-1,132.30
Quick Ratio
4.90
Shares on Issue (Fully Dilluted)
228m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
22 November 24 |
Immuron CEO presentation to Virtual Investor Summit
×
Immuron CEO presentation to Virtual Investor Summit |
18 November 24 |
2024 AGM Presentation
×
2024 AGM Presentation |
18 November 24 |
Results of Meeting
×
Results of Meeting |
14 November 24 |
Notification of cessation of securities - IMC
×
Notification of cessation of securities - IMC |
14 November 24 |
Change of Director's Interest Notice (DP RS)
×
Change of Director's Interest Notice (DP RS) |
29 October 24 |
Notification regarding unquoted securities - IMC
×
Notification regarding unquoted securities - IMC |
23 October 24 |
Change in substantial holding
×
Change in substantial holding |
18 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
16 October 24 |
IMC CEO to participate in Maxim Healthcare Conference
×
IMC CEO to participate in Maxim Healthcare Conference |
16 October 24 |
IMC CEO to participate in Maxim Healthcare - addendum
×
IMC CEO to participate in Maxim Healthcare - addendum |
15 October 24 |
Immuron Travelan continued strong sales growth
×
Immuron Travelan continued strong sales growth |
08 October 24 |
Application for quotation of securities - IMC
×
Application for quotation of securities - IMC |
08 October 24 |
Notice under section 708A
×
Notice under section 708A |
04 October 24 |
NMRC Reports Results for Campylobacter Clinical Study
×
NMRC Reports Results for Campylobacter Clinical Study |
03 October 24 |
Trading Halt
×
Trading Halt |
30 September 24 |
Annual Report
×
Annual Report |
30 September 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 September 24 |
Appendix 4G
×
Appendix 4G |
26 September 24 |
Immuron CEO presentation to Emerging Growth Conference
×
Immuron CEO presentation to Emerging Growth Conference |
05 September 24 |
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
×
Immuron Plans Phase 2 Trial for IMM-529 following FDA review |
30 August 24 |
Appendix 4E and Preliminary Final Report
×
Appendix 4E and Preliminary Final Report |
21 August 24 |
Immuron CEO presentation to Peak Biotech Showcase
×
Immuron CEO presentation to Peak Biotech Showcase |
16 August 24 |
New US DoD Research Award to develop enhanced Travelan
×
New US DoD Research Award to develop enhanced Travelan |
08 August 24 |
Immuron CEO presentation to MarketOpen Direct Connect
×
Immuron CEO presentation to MarketOpen Direct Connect |
07 August 24 |
Immuron CEO to host webinar on MarketOpen Direct Connect
×
Immuron CEO to host webinar on MarketOpen Direct Connect |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.